Plans are underway for Brazil's Ministry of Health to import a United States technology for producing anti-dengue-fever vaccine, as the government already assigned the Sao Paulo-based Butantan Institute to negotiate with U.S. researchers on this possible deal.

The agency's Secretary of Science Reynaldo Guimaraes said that the U.S. developed technology on anti-dengue-vaccine has shown "promising results". He however clarified that it would still take about three to four years to test its effectiveness.

Guimaraes said once the technology is acquired, the Butantan Institute would take charged with its overall improvement and development.

Considered as a deadly disease, dengue fever is a viral infection spread by the Aedes Aegypti mosquito. The hemorrhagic variant, which causes severe internal bleeding as blood vessels collapse, apparently kills one in 20 of the infected.